Skin Quality
“Skin quality” is useful only after the target attribute is named. Elasticity, firmness, surface roughness, hydration, dermal thickness, tone evenness, and radiance are different outcomes with different measurements and product-component explanations.
Define the attribute
Section titled “Define the attribute”| Attribute | Practical definition | Possible assessment |
|---|---|---|
| Elasticity | Ability to return toward the original position after deformation | Cutometer or standardized mechanical assessment |
| Firmness | Resistance to deformation across skin and supporting tissue | Validated scale or instrument matched to the area |
| Roughness or surface evenness | Microrelief, pores, lines, or textural irregularity | Standardized imaging or profilometry |
| Hydration | Water-related epidermal or dermal property | Corneometry or another defined instrument |
| Dermal thickness | Measured tissue thickness, not visual “plumpness” | Standardized high-frequency ultrasound |
| Radiance or glow | Composite visual perception | Validated scale or controlled imaging, with limitations stated |
A global skin-quality consensus separates firmness, surface evenness, tone evenness, and glow and emphasizes that their component attributes require different measurements (consensus 🔗).
Ask which component could explain the result
Section titled “Ask which component could explain the result”An observed early change can relate to:
- edema or prepared fluid
- non-cross-linked HA in a hybrid formulation
- a gel carrier
- surface hydration
- photography, lighting, or makeup
A later change can relate to:
- product-specific tissue response
- changes in dermal thickness or elasticity
- natural variation, concurrent treatment, or skincare
- regression to the mean or an unblinded rating
Do not attribute hydration improvement to “collagen” when the product contains HA and the study cannot separate the components.
Evidence map
Section titled “Evidence map”| Product context | Relevant evidence | Main limitation |
|---|---|---|
| Diluted or hyperdiluted CaHA | Consensus and small clinical studies report elasticity, pliability, or dermal-thickness outcomes | Much guidance is expert-led and many uses have been off-label |
| PLLA for laxity or skin attributes | Area-specific studies and consensus report gradual changes | Products, preparations, areas, and outcome tools vary |
| PDLLA + HA | Small product-specific studies report texture, elasticity, hydration, or global ratings | HA and PDLLA contributions are difficult to separate |
| PCL carrier-and-particle products | Structural and tissue-response literature may mention skin attributes | Do not infer a class-wide skin-quality indication |
Published hyperdilute CaHA guidance describes changed viscoelastic behavior and broad-distribution skin objectives, but it is Level 4 expert guidance rather than a universal label (CaHA practical guidance 🔗).
A 2026 prospective split-arm PLLA study included only 20 participants and 120 days of follow-up; it reported elasticity and skin-thickness changes but should not establish class-wide body performance (split-arm PLLA study 🔗).
A 2026 Juvelook 50 mg under-eye cohort included 15 women and used partly subjective skin-feature ratings. It is product-, area-, and protocol-specific evidence, not proof for every Juvelook presentation or facial area (Juvelook under-eye cohort 🔗).
Regulatory wording can be narrower
Section titled “Regulatory wording can be narrower”A published skin-quality endpoint does not automatically become approved intended use. For example:
- Korean Juvelook information describes temporary improvement of adult facial wrinkles through physical restoration
- the current Korean Radiesse page describes adult facial wrinkles and dorsal-hand volume loss
- the US 2026 Radiesse décolleté indication concerns correction of décolleté wrinkles with a specified 1:2 preparation
Check the regional regulation map before using “approved for skin quality.”
Design follow-up around the attribute
Section titled “Design follow-up around the attribute”Use the same instrument, lighting, position, skin preparation, and assessment conditions. Predefine the time point and avoid treating immediate edema or hydration as evidence of a delayed tissue response.
Documentation and follow-up provides the shared baseline record.
Decision output
Section titled “Decision output”Record the exact attribute, baseline measure, target area, product and component hypothesis, evidence type, local label status, co-interventions, and reassessment time.